D. E. Shaw & Co., Inc. Innoviva, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Innoviva, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 658,052 shares of INVA stock, worth $12.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

658,052

Holding current value

$12.4 Million

% of portfolio

0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$16.33 - $20.04 $23,074 - $28,316	-1,413 Reduced 0.21%	658,052 $12.7 Million
Q2 2024 Aug 14, 2024	SELL	$14.4 - $16.4 $1.08 Million - $1.23 Million	-75,265 Reduced 10.24%	659,465 $10.8 Million
Q1 2024 May 15, 2024	SELL	$14.56 - $16.78 $528,353 - $608,912	-36,288 Reduced 4.71%	734,730 $11.2 Million
Q4 2023 Feb 14, 2024	BUY	$12.32 - $16.27 $744,066 - $982,626	60,395 Added 8.5%	771,018 $12.4 Million
Q3 2023 Nov 14, 2023	BUY	$12.37 - $13.89 $1.18 Million - $1.32 Million	95,114 Added 15.45%	710,623 $9.23 Million
Q2 2023 Aug 14, 2023	SELL	$11.39 - $13.72 $805,261 - $969,990	-70,699 Reduced 10.3%	615,509 $7.84 Million
Q1 2023 May 15, 2023	SELL	$10.73 - $13.6 $3.14 Million - $3.98 Million	-292,916 Reduced 29.92%	686,208 $7.72 Million
Q4 2022 Feb 14, 2023	BUY	$11.8 - $13.78 $552,275 - $644,945	46,803 Added 5.02%	979,124 $13 Million
Q3 2022 Nov 14, 2022	SELL	$11.61 - $15.22 $2.57 Million - $3.37 Million	-221,413 Reduced 19.19%	932,321 $10.8 Million
Q2 2022 Aug 15, 2022	SELL	$14.32 - $19.88 $838,120 - $1.16 Million	-58,528 Reduced 4.83%	1,153,734 $17 Million
Q1 2022 May 16, 2022	BUY	$15.39 - $20.25 $6.36 Million - $8.37 Million	413,269 Added 51.72%	1,212,262 $23.5 Million
Q4 2021 Feb 14, 2022	SELL	$15.91 - $18.72 $431,272 - $507,443	-27,107 Reduced 3.28%	798,993 $13.8 Million
Q3 2021 Nov 15, 2021	SELL	$13.06 - $17.24 $127,452 - $168,245	-9,759 Reduced 1.17%	826,100 $13.8 Million
Q2 2021 Aug 16, 2021	SELL	$11.45 - $13.96 $2.45 Million - $2.98 Million	-213,539 Reduced 20.35%	835,859 $11.2 Million
Q1 2021 May 17, 2021	SELL	$11.06 - $12.87 $1.05 Million - $1.22 Million	-95,123 Reduced 8.31%	1,049,398 $12.5 Million
Q4 2020 Feb 16, 2021	SELL	$9.33 - $12.48 $843,870 - $1.13 Million	-90,447 Reduced 7.32%	1,144,521 $14.2 Million
Q3 2020 Nov 16, 2020	SELL	$10.33 - $14.49 $1.21 Million - $1.69 Million	-116,709 Reduced 8.63%	1,234,968 $12.9 Million
Q2 2020 Aug 14, 2020	SELL	$11.49 - $15.26 $2.11 Million - $2.8 Million	-183,418 Reduced 11.95%	1,351,677 $18.9 Million
Q1 2020 May 15, 2020	SELL	$8.11 - $15.23 $1.24 Million - $2.33 Million	-153,310 Reduced 9.08%	1,535,095 $18.1 Million
Q4 2019 Feb 14, 2020	BUY	$10.28 - $14.38 $1.55 Million - $2.17 Million	150,974 Added 9.82%	1,688,405 $23.9 Million
Q3 2019 Nov 14, 2019	SELL	$10.05 - $14.55 $4.22 Million - $6.12 Million	-420,301 Reduced 21.47%	1,537,431 $16.2 Million
Q2 2019 Aug 14, 2019	SELL	$13.1 - $14.95 $2.34 Million - $2.67 Million	-178,386 Reduced 8.35%	1,957,732 $28.5 Million
Q1 2019 May 15, 2019	BUY	$13.69 - $20.06 $2.46 Million - $3.61 Million	179,798 Added 9.19%	2,136,118 $30 Million
Q4 2018 Feb 14, 2019	BUY	$13.96 - $18.26 $14 Million - $18.3 Million	1,001,636 Added 104.92%	1,956,320 $34.1 Million
Q3 2018 Nov 14, 2018	BUY	$13.63 - $15.7 $6.58 Million - $7.58 Million	482,603 Added 102.23%	954,684 $14.5 Million
Q2 2018 Aug 14, 2018	BUY	$13.44 - $17.59 $3.72 Million - $4.87 Million	276,624 Added 141.53%	472,081 $6.52 Million
Q1 2018 May 15, 2018	SELL	$13.8 - $16.99 $5.23 Million - $6.44 Million	-379,035 Reduced 65.98%	195,457 $3.26 Million
Q4 2017 Feb 14, 2018	SELL	$11.73 - $14.75 $3.48 Million - $4.38 Million	-297,091 Reduced 34.09%	574,492 $8.15 Million
Q3 2017 Nov 14, 2017	BUY	$12.06 - $14.12 $10.5 Million - $12.3 Million	871,583	871,583 $12.3 Million

Others Institutions Holding INVA

# of Institutions

229

Shares Held

79.2M

Call Options Held

37.6K

Put Options Held

300

View Full List

About Innoviva, Inc.

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.32B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

More about INVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account